Results 131 to 140 of about 60,444 (298)

Daratumumab plus bortezomib and dexamethasone (Dara‐VD) in newly diagnosed Mayo 2004 stage IIIA and IIIB light‐chain amyloidosis: Long‐term follow‐up results from a prospective phase 2 study

open access: yesBritish Journal of Haematology, EarlyView.
Summary Anti‐CD38 monoclonal antibodies dramatically improve the prognosis in immunoglobulin light‐chain (AL) amyloidosis, yet patients with end‐stage (Mayo 2004 IIIB) disease are typically excluded from prospective trials. To evaluate the daratumumab plus bortezomib and dexamethasone (Dara‐VD) regimen in Mayo 2004 stage III patients, we conducted a ...
Gao Xue‐min   +7 more
wiley   +1 more source

PTPσ inhibitors promote hematopoietic stem cell regeneration. [PDF]

open access: yes, 2019
Receptor type protein tyrosine phosphatase-sigma (PTPσ) is primarily expressed by adult neurons and regulates neural regeneration. We recently discovered that PTPσ is also expressed by hematopoietic stem cells (HSCs).
Chute, John P   +17 more
core   +1 more source

A herbal formula, SYKT, reverses doxorubicin-induced myelosuppression and cardiotoxicity by inhibiting ROS-mediated apoptosis

open access: yesMolecular Medicine Reports, 2017
Doxorubicin (DOX) is an antineoplastic drug widely used for the treatment of various types of cancer; however, it can induce severe side effects, such as myelosuppression and cardiotoxicity. Sanyang Xuedai (SYKT) is a natural medicine originating from an
Ting Chen   +9 more
semanticscholar   +1 more source

Targeting Inflammation and Immune Regulation in Chronic Inflammation Associated Cancers

open access: yesCancer Science, EarlyView.
Chronic inflammation sustains activation of key inflammatory pathways, including Nuclear factor kappa B (NF‐κB), Interleukin‐6‐signal transducer and activator of transcription 3 (IL6‐STAT3), Phosphoinositide 3‐kinase/Akt (PI3K/Akt), and Wingless/β‐catenin (Wnt/β‐catenin) signaling. This promotes immune dysregulation through the expansion and functional
Lawan Rabiu   +5 more
wiley   +1 more source

Tolerability of linezolid in patients with drug-resistant TB in Daru, Western Province, PNG

open access: yesPublic Health Action
SETTING: Linezolid (LZD) has emerged as a critical agent and core component of regimens to treat drug-resistant TB (DR-TB); however, there are ongoing uncertainties regarding its safety and the optimal dosing approach. Since 2016, linezolid has been used
M. Boga   +4 more
doaj   +1 more source

Exosomal miR-122-5p is Related to the Degree of Myelosuppression Caused by Chemotherapy in Patients with Colorectal Cancer

open access: yesCancer Management and Research, 2021
Jinbao Chen,1,* Wentao Wu,1,* Xue He,1 Linlin Jia,1 Jiahua Yang,1 Xianke Si,1 Kun Yu,1 Sen Li,1 Yanyan Qiu,1 Ke Xu,2 Peihao Yin,1,3 Yijun Cao,1 Qiong Li,4 Wei Li1 1Department of General Surgery, Putuo Hospital, Shanghai University of Traditional ...
Chen J   +13 more
doaj  

Intraocular Metastasis: Differential Diagnosis and Management

open access: yesClinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Intraocular metastases represent the most common type of malignant intraocular tumour in adults. These commonly affect the choroid but can also involve the iris, ciliary body, retina, vitreous, optic disc or lens. Breast and lung cancer are the most common origins of intraocular metastases.
Genovefa Μachairoudia   +3 more
wiley   +1 more source

Prospective Observational Study on the Risk Factors of Chemotherapy-Induced Myelosuppression and Its Management in a Tertiary Care Hospital

open access: yesIndian Journal of Medical and Paediatric Oncology
Introduction Myelosuppression is a commonly observed dose-limiting side effect of majority of chemotherapeutic drugs, characterized by a decrease in blood cell production.
D. Keziah   +3 more
doaj   +1 more source

Frontline Therapy in Diffuse Large B‐Cell Lymphoma: Evolving Standards, Biological Insights, and Future Directions

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) remains the most common aggressive lymphoma, representing a biologically heterogeneous disease with diverse clinical behaviors. For more than two decades, R‐CHOP has been the cornerstone of frontline treatment, curing approximately two‐thirds of patients.
Mamdouh Skafi   +12 more
wiley   +1 more source

Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies

open access: yesCancer Management and Research, 2021
Maen Hussein,1 Marina Maglakelidze,2 Donald A Richards,3 Marielle Sabatini,4 Todd A Gersten,5 Keith Lerro,6 Ivan Sinielnikov,7 Alexander Spira,8,9 Yili Pritchett,10 Joyce M Antal,10 Rajesh Malik,10 J Thaddeus Beck11 1Florida Cancer Specialists, Leesburg,
Hussein M   +11 more
doaj  

Home - About - Disclaimer - Privacy